Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma
- 4 May 2020
- journal article
- research article
- Published by Elsevier BV in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (9), 3021-3028.e2
- https://doi.org/10.1016/j.jaip.2020.03.051
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- Department of Health and Human Services (HHSN272200900052C, HHSN272201000052I)
- National Center for Research Resources
- National Center for Advancing Translational Sciences (UL1TR000154, UL1TR000040, UL1TR000150, UL1TR000451, UL1TR001105, 5R01AI098077, 1UL1RR025780, UL1TR001082, N01-AI-90052, UL1TR000075, UL1TR000077-04, K23-AI-104780)
- TrialShare (UM1AI109565)
This publication has 21 references indexed in Scilit:
- High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effectsJournal of Allergy and Clinical Immunology, 2013
- Reassessment of Omalizumab-Dosing Strategies and Pharmacodynamics in Inner-City Children and AdolescentsThe Journal of Allergy and Clinical Immunology: In Practice, 2013
- Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthmaJournal of Allergy and Clinical Immunology, 2012
- Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City ChildrenThe New England Journal of Medicine, 2011
- The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspectiveAllergy, 2010
- PrefaceJournal of Allergy and Clinical Immunology, 2007
- Severe exacerbations predict excess lung function decline in asthmaEuropean Respiratory Journal, 2007
- Predicting and evaluating response to omalizumab in patients with severe allergic asthmaRespiratory Medicine, 2007
- Omalizumab for AsthmaThe New England Journal of Medicine, 2006
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004